1800-272-662
Shopping Cart 0
countryflagAU
Login

Avecho Biotechnology Ltd

Healthcare AU AVE

0.01AUD
-(-%)

Last update at 2026-03-13T03:31:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0030.01
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap36.73M
  • Volume7216651
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.81817M
  • Revenue TTM1.24M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.89M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.41251M -3.12200M -4.51200M -2.34239M -3.41612M
Minority interest - - - - -
Net income -4.41662M -3.12200M -3.43700M -2.34874M -4.57013M
Selling general administrative - 1.99M 2.43M 2.26M 2.60M
Selling and marketing expenses - 0.05M 0.83M - -
Gross profit 0.75M 0.67M -0.04380M 0.87M 0.51M
Reconciled depreciation - 0.14M 0.18M 0.23M 0.67M
Ebit -6.00430M -3.06488M -3.42170M -2.56639M -3.40614M
Ebitda -5.86721M -2.92000M -3.24300M -2.33604M -2.97755M
Depreciation and amortization 0.14M 0.14M 0.18M 0.23M 0.43M
Non operating income net other - - - - -
Operating income -6.00430M -4.95900M -4.58900M -2.56639M -3.40614M
Other operating expenses 7.24M 6.09M 5.06M 4.19M 5.34M
Interest expense 0.46M 0.06M 0.02M 0.00635M 0.00997M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.06M 0.04M 0.00435M 0.00083M
Net interest income - 0.00448M 0.02M -0.00200M -0.01480M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.99588M -1.63546M -1.07600M 0.00635M 1.15M
Total revenue 1.24M 1.13M 0.47M 1.21M 0.79M
Total operating expenses 6.76M 5.63M 4.55M 3.93M 5.06M
Cost of revenue 0.49M 0.46M 0.52M 0.34M 0.29M
Total other income expense net -0.40821M 1.84M 0.08M 0.22M -0.00997M
Discontinued operations - - - - -
Net income from continuing ops - -3.12205M -3.43656M -2.34239M -5.15367M
Net income applicable to common shares - -3.12205M -3.43656M -2.34239M -3.41612M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.11M 5.00M 7.32M 3.35M 5.25M
Intangible assets - - - 0.03M 0.10M
Earning assets - - - - -
Other current assets 0.18M 1.73M 0.30M 0.24M 0.22M
Total liab 5.55M 1.73M 0.94M 0.92M 0.71M
Total stockholder equity 1.56M 3.27M 6.38M 2.42M 4.54M
Deferred long term liab - - - - -
Other current liab 0.59M 0.59M 0.51M 0.48M 0.54M
Common stock 246.90M 244.61M 244.61M 237.53M 237.60M
Capital stock - 244.61M - 237.53M 237.60M
Retained earnings -245.99550M -269.39175M -239.62752M -264.10433M -262.06726M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - -
Cash 4.66M 2.37M 5.50M 1.47M 3.26M
Cash and equivalents - - - 1.47M 3.26M
Total current liabilities 0.71M 1.71M 0.84M 0.75M 0.70M
Current deferred revenue - - 0.16M - -
Net debt -4.64902M -1.29787M -5.32925M -1.22213M -3.17085M
Short term debt 0.01M 1.06M 0.08M 0.07M 0.08M
Short long term debt - 0.98M - - -
Short long term debt total 0.01M 1.08M 0.18M 0.25M 0.09M
Other stockholder equity - 0.00000M - 0.02M 29.00M
Property plant equipment - - - 0.47M 0.34M
Total current assets 7.06M 4.81M 7.00M 2.85M 4.81M
Long term investments - - - - -
Net tangible assets - - - 2.40M 4.43M
Short term investments - - - 0.09M -
Net receivables 2.20M 0.57M 1.10M 0.75M 1.13M
Long term debt - - - - -
Inventory 0.00807M 0.14M 0.10M 0.40M 0.20M
Accounts payable 0.10M 0.06M 0.09M 0.19M 0.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.65M 28.06M 1.40M 29.00M 29.00M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.02M -0.00000M - -
Deferred long term asset charges - - - - -
Non current assets total 0.05M 0.19M 0.32M 0.49M 0.44M
Capital lease obligations - 0.10M - 0.25M 0.09M
Long term debt total - - - 0.18M 0.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01573M - -0.05312M -0.25873M
Change to liabilities - - - 0.03M 0.03M
Total cashflows from investing activities - -0.01573M 0.00000M -0.05312M -0.20229M
Net borrowings - 0.93M - -0.08021M -0.07232M
Total cash from financing activities 1.19M 0.85M 7.22M -0.07822M 4.69M
Change to operating activities - - - 0.04M 0.04M
Net income -4.41662M -3.12205M -3.43656M -2.34874M -5.15367M
Change in cash 2.29M -3.12986M 4.04M -1.79655M 1.39M
Begin period cash flow 2.37M 5.50M 1.47M 3.26M 1.87M
End period cash flow 4.66M 2.37M 5.50M 1.47M 3.26M
Total cash from operating activities 1.10M -3.96872M -3.17996M -2.27299M 0.43M
Issuance of capital stock - - 8.00M 0.00199M 5.06M
Depreciation 0.14M 0.14M 0.18M 0.08M 0.43M
Other cashflows from investing activities - -0.01573M -0.00001M - 0.00053M
Dividends paid - - - - -
Change to inventory 0.13M -0.04034M -0.06073M -0.20525M -0.09673M
Change to account receivables 0.04M -1.14690M -0.35357M 0.40M -0.67165M
Sale purchase of stock - 0.00000M -0.71653M 0.00199M -0.29420M
Other cashflows from financing activities -0.08375M -0.07693M -0.07092M -0.08021M -0.07232M
Change to netincome - - - 0.18M 0.58M
Capital expenditures 0.00000M 0.00000M 0.00001M 0.05M 0.20M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.92M -0.92506M -0.39005M 1.04M 0.52M
Stock based compensation - 0.01M 0.10M - -
Other non cash items 0.46M -0.06649M 0.37M 2.27M 4.73M
Free cash flow 1.10M -3.96872M -3.17995M -2.32611M -0.20282M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVE
Avecho Biotechnology Ltd		 - -% 0.01 - 4.78 29.68 23.55 25.77 -6.5575
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Avecho Biotechnology Ltd

Hallmarc Business Park, Clayton, VIC, Australia, 3168

Key Executives

Name Title Year Born
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Exec. Officer NA
Dr. Roksan Libinaki Ph.D. Chief Operating Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.